Celecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME

doi:10.3748/wjg.v23.i29.5304

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 23, Issue 29

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (11475)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-3) series.

Item

Count

PDF

748

WORD

363

HTML

6416

Figures (1-3)

263

Tables (1-3)

227

Sum=8017

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1201

Download

2257

Sum=3458

Aug 7, 2017 (publication date) through Jan 2, 2025

Times Cited of This Article

Times Cited (44)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastroenterol. Aug 7, 2017; 23(29): 5304-5312
Published online Aug 7, 2017. doi: 10.3748/wjg.v23.i29.5304

Table 2 Liver lesions assessment after celecoxib, BPC 157, L-NAME, L-arginine

Medication (/kg intraperitoneally) immediately after celecoxib 1 g/kg intraperitoneally	Time after celecoxib	Liver lesions assessment
		Microscopic assessment, Score (0-3), Min/Med/Max			Serum enzymes values (IU/L), means ± SD
		steatosis	congestion	necrosis	ALT	AST
Control, saline 5 mL	24 h	2/2/3	2/2/3	2/2/3	352 ± 12	75 ± 8
Control, saline 5 mL	48 h	2/3/3	2/2/3	2/2/3	356 ± 18	84 ± 9
BPC 157 10 μg	24 h	1/1/1^a	1/1/2^a	1/1/1^a	138 ± 14^a	41 ± 11^a
BPC 157 10 μg	48 h	1/1/1^a	1/1/2^a	1/1/1^a	63 ± 12^a	35 ± 12^a
BPC 157 10 ng	24 h	1/1/1^a	1/1/2^a	1/1/1^a	154 ± 13^a	45 ± 8^a
BPC 157 10 ng	48 h	1/1/2^a	1/1/2^a	1/1/1^a	72 ± 19^a	40 ± 7^a
BPC 157 1 ng	24 h	1/1/1^a	1/1/2^a	1/1/1^a	170 ± 15^a	48 ± 10^a
BPC 157 1 ng	48 h	1/1/2^a	1/1/2^a	1/1/1^a	80 ± 15^a	43 ± 8^a
L-NAME 5 mg	24 h	2/3/3	2/2/3	2/2/3	375 ± 11	86 ± 12
L-NAME 5 mg	48 h	3/3/3	2/3/3	2/2/3	400 ± 12	80 ± 10
L-arginine 100 mg	24 h	1/2/2^a	1/2/2^a	1/2/2^a	315 ± 14^a	68 ± 14^a
L-arginine 100 mg	48 h	1/2/2^a	1/2/2^a	1/2/2^a	300 ± 21^a	65 ± 10^a
L-NAME 5 mg + L-arginine 100 mg	24 h	1/2/2^a	1/2/2^a	1/2/2^a	293 ± 17^a	68 ± 9^a
L-NAME 5 mg + L-arginine 100 mg	48 h	2/2/2	2/2/3	2/2/2	270 ± 15^a	73 ± 11^a
L-NAME 5 mg + BPC 157 10 μg	24 h	1/1/1^a	1/2/2^a	1/1/1^a	170 ± 15^a	69 ± 9^a
L-NAME 5 mg + BPC 157 10 μg	48 h	1/1/2^a	1/2/2^a	1/1/1^a	150 ± 12^a	55 ± 13^a
L-NAME 5 mg + BPC 157 10 ng	24 h	1/1/1^a	1/2/2^a	1/1/1^a	210 ± 16^a	70 ± 7^a
L-NAME 5 mg + BPC 157 10 ng	48 h	1/1/2^a	1/2/2^a	1/1/1^a	182 ± 14^a	60 ± 8^a
L-arginine 100 mg + BPC 157 10 μg	24 h	1/1/1^a	1/1/1^a	1/1/1^a	165 ± 25^a	55 ± 8^a
L-arginine 100 mg + BPC 157 10 μg	48 h	1/1/2^a	1/1/1^a	1/1/1^a	160 ± 18^a	45 ± 8^a
L-arginine 100 mg + BPC 157 10 ng	24 h	1/1/1^a	1/1/2^a	1/1/1^a	190 ± 11^a	63 ± 10^a
L-arginine 100 mg + BPC 157 10 ng	48 h	1/1/2^a	1/1/2^a	1/1/1^a	170 ± 13^a	55 ± 9^a
L-NAME 5 mg + L-arginine 100 mg + BPC 157 10 μg	24 h	1/1/2^a	1/1/2^a	1/1/1^a	167 ± 11^a	57 ± 10^a
L-NAME 5 mg + L-arginine 100 mg + BPC 157 10 μg	48 h	1/1/2^a	1/1/2^a	1/1/1^a	176 ± 14^a	57 ± 8^a
L-NAME 5 mg + L-arginine 100 mg + BPC 157 10 ng	24 h	1/1/2^a	1/1/2^a	1/1/1^a	202 ± 9^a	62 ± 7^a
L-NAME 5 mg + L-arginine 100 mg + BPC 157 10 ng	48 h	1/1/2^a	1/1/2^a	1/1/1^a	190 ± 12^a	65 ± 8^a

^aP < 0.05 vs control.

Citation: Drmic D, Kolenc D, Ilic S, Bauk L, Sever M, Zenko Sever A, Luetic K, Suran J, Seiwerth S, Sikiric P. Celecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME. World J Gastroenterol 2017; 23(29): 5304-5312
URL: https://www.wjgnet.com/1007-9327/full/v23/i29/5304.htm
DOI: https://dx.doi.org/10.3748/wjg.v23.i29.5304